Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.33B | 2.32B | 2.38B | 2.42B | 1.79B |
Gross Profit | 1.10B | 1.10B | 1.14B | 1.18B | 804.47M |
EBITDA | 66.72M | 35.84M | 136.66M | 190.36M | -59.66M |
Net Income | -18.89M | -16.83M | 71.92M | 114.85M | -56.03M |
Balance Sheet | |||||
Total Assets | 1.34B | 1.33B | 1.46B | 1.56B | 1.59B |
Cash, Cash Equivalents and Short-Term Investments | 34.01M | 35.16M | 47.99M | 320.52M | 215.09M |
Total Debt | 485.09M | 522.94M | 580.43M | 632.64M | 734.04M |
Total Liabilities | 788.57M | 758.69M | 849.46M | 959.63M | 1.02B |
Stockholders Equity | 546.97M | 571.20M | 606.97M | 602.47M | 566.76M |
Cash Flow | |||||
Free Cash Flow | 46.75M | 34.49M | -224.82M | 185.97M | 133.61M |
Operating Cash Flow | 87.89M | 94.80M | -164.88M | 239.87M | 157.74M |
Investing Cash Flow | -41.13M | -60.00M | -59.93M | -33.90M | -24.02M |
Financing Cash Flow | -47.00M | -47.58M | -45.53M | -101.17M | -3.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | $227.87M | 6.70 | 41.77% | 2.15% | -2.24% | -33.43% | |
63 Neutral | $242.31M | ― | -3.07% | ― | 1.85% | 22.34% | |
63 Neutral | $16.78B | 10.88 | -7.08% | 3.04% | 1.73% | -25.15% | |
57 Neutral | $137.20M | ― | -9.20% | 7.12% | -4.22% | -386.70% | |
54 Neutral | $234.75M | 1,211.82 | 0.23% | ― | 3.01% | ― | |
52 Neutral | $247.41M | ― | -29.52% | ― | 1.85% | -337.77% | |
44 Neutral | $115.61M | ― | -521.67% | ― | -12.15% | 75.86% |
On June 26, 2025, Genesco held its annual shareholder meeting virtually from its headquarters in Nashville, Tennessee, where shareholders voted on several key matters. All nine director nominees were elected, and shareholders approved the executive compensation plan, the Third Amended and Restated 2020 Equity Incentive Plan, and the appointment of Deloitte & Touche as the independent accountants for the fiscal year.
The most recent analyst rating on (GCO) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Genesco stock, see the GCO Stock Forecast page.